Kura Oncology CFO reports no trades or derivatives

Kura Oncology’s Chief Financial Officer filed an initial Form 3 that reports no current transactions or derivative holdings in KURA securities.

Available on EDGAR 09/10/2026 - 04:25 PM EDT Accepted by SEC EDGAR 09/10/2026 - 04:25 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Kura Oncology, Inc. (KURA) reported that its Chief Financial Officer, Jennifer Fulk, has filed an initial statement of beneficial ownership of securities on Form 3. The submission lists no reportable transactions, acquisitions, or dispositions of Kura Oncology securities and shows no derivative positions.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the new Form 3 filing mean for KURA?

The Form 3 shows that Kura Oncology’s Chief Financial Officer, Jennifer Fulk, has filed an initial statement of beneficial ownership. The report lists no transactions and no derivative holdings in KURA securities as of the filing.

Did the KURA Chief Financial Officer buy or sell any shares in this Form 3?

No. The Form 3 for Kura Oncology’s Chief Financial Officer reports no purchases, no sales, and no other transactions in KURA securities.

Does the KURA Form 3 show any stock options or other derivatives?

No. The structured disclosure indicates no derivative positions such as options or similar instruments reported for the Chief Financial Officer in this Form 3.

Who is the reporting person in this KURA Form 3?

The reporting person is Jennifer Fulk, who is identified as the Chief Financial Officer of Kura Oncology, Inc.

Does this KURA Form 3 indicate use of a Rule 10b5-1 trading plan?

No. The available data do not indicate that any transactions were made or that a Rule 10b5-1 trading plan is associated with this Form 3.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fulk Jennifer

(Last) (First) (Middle)

C/O KURA ONCOLOGY, INC.

4930 DIRECTORS PLACE, SUITE 500

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
09/08/2026

3. Issuer Name and Ticker or Trading Symbol
Kura Oncology, Inc. [ KURA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	Teresa Bair, Attorney-in-fact for Jennifer Fulk	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)